Cargando…
Ac-EAZY! Towards GMP-Compliant Module Syntheses of (225)Ac-Labeled Peptides for Clinical Application
The application of (225)Ac (half-life T(1/2) = 9.92 d) dramatically reduces the activity used for peptide receptor radionuclide therapy by a factor of 1000 in comparison to (90)Y, (177)Lu or (188)Re while maintaining the therapeutic outcome. Additionally, the range of alpha particles of (225)Ac and...
Autores principales: | Pretze, Marc, Kunkel, Falk, Runge, Roswitha, Freudenberg, Robert, Braune, Anja, Hartmann, Holger, Schwarz, Uwe, Brogsitter, Claudia, Kotzerke, Jörg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308848/ https://www.ncbi.nlm.nih.gov/pubmed/34358076 http://dx.doi.org/10.3390/ph14070652 |
Ejemplares similares
-
Successful Combination of Olaparib and (225)Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation
por: Kröcher, Anke, et al.
Publicado: (2023) -
Development of [(225)Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
por: Hooijman, Eline L., et al.
Publicado: (2021) -
[(225)Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [(225)Ac]Ac-PSMA-617
por: Busslinger, Sarah D., et al.
Publicado: (2022) -
Psoralen as a Photosensitizers for Photodynamic Therapy by Means of In Vitro Cherenkov Light
por: Hübinger, Lisa, et al.
Publicado: (2022) -
Cure of Disseminated Human Lymphoma with [(225)Ac]Ac-Ofatumumab in a Preclinical Model
por: Longtine, Mark S., et al.
Publicado: (2023)